<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>tumor vascularization and therapy resistance &#8211; Science</title>
	<atom:link href="https://scienmag.com/tag/tumor-vascularization-and-therapy-resistance/feed/" rel="self" type="application/rss+xml" />
	<link>https://scienmag.com</link>
	<description></description>
	<lastBuildDate>Tue, 27 Oct 2026 10:46:52 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://scienmag.com/wp-content/uploads/2024/07/cropped-scienmag_ico-32x32.jpg</url>
	<title>tumor vascularization and therapy resistance &#8211; Science</title>
	<link>https://scienmag.com</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">73899611</site>	<item>
		<title>Cancer Stem Cells, Immune Evasion and Vascularization Drive Therapy Resistance in Brain Tumors</title>
		<link>https://scienmag.com/cancer-stem-cells-immune-evasion-and-vascularization-drive-therapy-resistance-in-brain-tumors/</link>
		
		<dc:creator><![CDATA[Nathaniel Bowman]]></dc:creator>
		<pubDate>Tue, 27 Oct 2026 10:46:52 +0000</pubDate>
				<category><![CDATA[Medicine]]></category>
		<category><![CDATA[atypical teratoid rhabdoid tumor]]></category>
		<category><![CDATA[blood-brain barrier]]></category>
		<category><![CDATA[blood-brain barrier and tumor heterogeneity]]></category>
		<category><![CDATA[brain tumors]]></category>
		<category><![CDATA[cancer stem cells]]></category>
		<category><![CDATA[central nervous system tumors]]></category>
		<category><![CDATA[Glioblastoma]]></category>
		<category><![CDATA[immune evasion]]></category>
		<category><![CDATA[immune evasion in brain tumors]]></category>
		<category><![CDATA[mechanisms of resistance in brain tumors]]></category>
		<category><![CDATA[medulloblastoma]]></category>
		<category><![CDATA[neuro-oncology]]></category>
		<category><![CDATA[neuro-oncology treatment challenges]]></category>
		<category><![CDATA[overcoming therapeutic resistance in neuro-oncology]]></category>
		<category><![CDATA[role of immune microenvironment in therapy failure]]></category>
		<category><![CDATA[surgical and radiotherapy outcomes in brain cancer]]></category>
		<category><![CDATA[targeted therapies for neuro-oncology]]></category>
		<category><![CDATA[therapeutic resistance]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<category><![CDATA[tumor microenvironment in CNS cancers]]></category>
		<category><![CDATA[tumor vascularization and therapy resistance]]></category>
		<category><![CDATA[vascularization]]></category>
		<category><![CDATA[vascularization and tumor survival in CNS]]></category>
		<guid isPermaLink="false">https://scienmag.com/?p=351900</guid>

					<description><![CDATA[A new review in the Journal of Translational Medicine examines how cancer stem cells, vascularization and immune evasion contribute to therapeutic resistance in central nervous system tumors.]]></description>
										<content:encoded><![CDATA[<p>Therapeutic resistance remains one of the most stubborn obstacles in neuro-oncology, and a new review published in the Journal of Translational Medicine examines why treatments so often fail in tumors of the central nervous system. The article, authored by Le Hien Giang, Tai-Tong Wong and Che-Chang Chang and published on 27 October 2026, synthesizes the biological mechanisms that allow CNS tumors to survive surgery, radiotherapy, chemotherapy and emerging targeted therapies, with particular attention to cancer stem cells, vascularization and the tumor immune microenvironment.</p>
<p>The review emphasizes that neoplasms of the central nervous system are a highly heterogeneous group of malignant tumors affecting both pediatric and adult populations. They span a broad spectrum of histological subtypes and biological behaviors, which means therapeutic strategies must be tailored to tumor type and individual patient characteristics. Standard treatment typically combines surgical resection, radiotherapy, chemotherapy and emerging targeted therapies, yet the efficacy of these interventions varies considerably, and long-term remission and survival outcomes remain difficult to achieve.</p>
<p>According to the authors, resistance is multifactorial. Substantial contributions come from the blood-brain barrier, intratumoral heterogeneity and the tumor microenvironment. Together these factors form a complex, adaptive network that enables tumor survival and proliferation even under aggressive treatment regimens. The review highlights how the interplay among cellular plasticity, vascular and microenvironmental adaptations, and immune evasion contributes to therapeutic failure and tumor recurrence.</p>
<p>An important caveat runs through the analysis: mechanistic evidence is unevenly distributed across CNS malignancies. The evidence synthesized in the review is derived primarily from glioblastoma, with additional studies in medulloblastoma and atypical teratoid rhabdoid tumor. This means the picture of resistance built from these tumor types may not generalize uniformly to every CNS neoplasm, and the authors frame their synthesis accordingly rather than as a uniform account of all brain tumors.</p>
<p> The authors argue that a better understanding of these interlocking mechanisms may facilitate the development of more effective and personalized therapeutic strategies for CNS tumors. As a review article, the work consolidates existing findings rather than presenting new experimental data, and its conclusions reflect the state of the current literature on glioblastoma, medulloblastoma and atypical teratoid rhabdoid tumor.</p>
<p><strong>Subject of Research:</strong> Mechanisms of therapeutic resistance in central nervous system tumors, including cancer stem cells, vascularization and immune evasion</p>
<p><strong>Article Title:</strong> Unraveling therapeutic resistance in brain tumors: the roles of cancer stem cells, immune evasion, and vascularization</p>
<p><strong>Article References:</strong> Giang, L. H., Wong, T.-T., &amp; Chang, C.-C. (2026). Unraveling therapeutic resistance in brain tumors: the roles of cancer stem cells, immune evasion, and vascularization. <em>Journal of Translational Medicine</em>. <a href="https://doi.org/10.1186/s12967-026-09142-6" rel="noopener noreferrer">https://doi.org/10.1186/s12967-026-09142-6</a></p>
<p><strong>Image Credits:</strong> AI Generated</p>
<p><strong>DOI:</strong> <a href="https://doi.org/10.1186/s12967-026-09142-6" rel="noopener noreferrer">10.1186/s12967-026-09142-6</a></p>
<p><strong>Keywords:</strong> brain tumors, therapeutic resistance, cancer stem cells, immune evasion, vascularization, glioblastoma, medulloblastoma, atypical teratoid rhabdoid tumor, tumor microenvironment, blood-brain barrier, neuro-oncology, central nervous system tumors</p>
]]></content:encoded>
					
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">351900</post-id>	</item>
	</channel>
</rss>
